BioAtla, Inc. Share Price & Technical Analysis
BCAB · $3.69 (+1.93%)
Healthcare / Biotechnology
$3.69
+1.93%
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); an…
Price chart
Seasonality
May has 0 positive and 5 negative years (last 5 years shown)
-12% return in May, -19% avg return in past 3 year May month.
-118% return in 2026, -39% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -57% | -1% | -16% | -32% | -12% | – | – | – | – | – | – | – | -118% |
| 25 | -24% | -30% | 2% | 43% | -16% | -5% | -8% | 28% | 46% | 2% | 35% | -43% | 32% |
| 24 | -21% | 41% | 28% | -36% | -33% | -10% | 35% | -4% | 1% | -1% | -14% | -65% | -78% |
| 23 | -54% | -21% | -11% | 23% | -7% | -5% | -1% | -15% | -32% | -12% | 24% | 39% | -72% |
| 22 | -53% | -32% | -21% | -31% | -32% | 15% | 19% | 158% | -12% | -11% | 57% | -24% | 34% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Weak
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcinoma. The company is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$7.55M
P/E ratio
—
52W high
$71.50
52W low
$3.26
Volume
16,919
Beta
0.79
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is BioAtla, Inc. share price today?
- BioAtla, Inc. (BCAB) last traded around $3.69 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does BCAB have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for BCAB. Download the app for real-time alerts.
- How can I analyze BioAtla, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.